Vir Biotechnology (VIR -5.5%) initiates a
Phase 1 clinical trial evaluating VIR-3434 for the potential treatment
of chronic hepatitis B virus (HBV) infection. The study will progress
from healthy volunteers to chronic HBV patients. Preliminary data should
be available in 2021.
VIR-3434 is an HBV-neutralizing monoclonal
antibody designed to block the entry of 10 HBV genotypes into liver
cells called hepatocytes as well as reducing levels of virions (complete
infective forms of the virus outside of host cells) and subviral
particles in the blood.
The company says it has been engineered to also act as a therapeutic vaccine.
Its other HBV candidate, VIR-2218, is currently in Phase 2 development.
https://seekingalpha.com/news/3577893-vir-biotech-launches-early-stage-study-of-hbv-candidate
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.